1220P - Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours

Jason J Luke ,H Fang,Mustafa Khasraw ,Ki Young Chung ,Si Fan ,Kristi R Kelly ,Michael A Mcdevitt ,Maulik Patel ,Christophe Le Tourneau ,Joel S Hayflick ,Antoine Hollebecque ,William R Henner ,Steven Kao ,Frank Tsai ,Philippe Cassier ,Kathryn Allaire ,A W Tolcher ,Lawrence Fong ,Vivek Subbiah ,Fabrice Barlési

doi:10.1093/annonc/mdz253.046

1220P - Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours

Jason J Luke , H Fang + Show 18 more

Open Access

https://doi.org/10.1093/annonc/mdz253.046

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 5	License type: publisher-specific-oa

#Research Grant #Funding Institution + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1220P - Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours

Full Text